CRISPR Therapeutics AG (CRSP) — Analyst outlook / Analyst consensus target is. Based on 38 analyst ratings, the consensus is bullish — 22 Buy, 14 Hold, 2 Sell.
The consensus price target is $65.00 (low: $33.00, high: $82.00), representing an upside of 14.3% from the current price $56.86.
Analysts estimate Earnings Per Share (EPS) of $-5.16 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-4.34 vs est $-5.16 (beat +15.9%). 2025: actual $-6.47 vs est $-6.21 (missed -4.1%). Analyst accuracy: 89%.
CRSP Stock — 12-Month Price Forecast
$65.00
▲ +14.32% Upside
Average Price Target
Based on 38 Wall Street analysts offering 12-month price targets for CRISPR Therapeutics AG, the average price target is $65.00, with a high forecast of $82.00, and a low forecast of $33.00.
The average price target represents a +14.32% change from the last price of $56.86.
Highest Price Target
$82.00
Average Price Target
$65.00
Lowest Price Target
$33.00
CRSP Analyst Ratings
Buy
Based on 38 analysts giving stock ratings to CRISPR Therapeutics AG in the past 3 months
EPS Estimates — CRSP
89%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$4.34
vs Est –$5.16
▲ 18.9% off
2025
Actual –$6.47
vs Est –$6.21
▼ 4.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — CRSP
16%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.035B
vs Est $0.011B
▲ 68.1% off
2025
Actual $0.004B
vs Est $0.007B
▼ 100.9% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
